Real-world Experience With Generic Tofacitinib in Axial Spondyloarthritis From North India
Indian Journal of Rheumatology · 13.11.2026
DOI: 10.1177/09733698261488955 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Rheumatology, online erschienen am 13.11.2026. Verfasst von Sanjiv Kapoor und 3 weiteren Autor:innen. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Axial spondyloarthritis (AxSpA) severely affects quality of life, underscoring the need for effective treatments. Tofacitinib, recently approved in India for active ankylosing spondylitis, a subset of AxSpA, has shown significant efficacy and a favourable safety profile. However, real-world data in Indian AxSpA patients remain limited. This retrospective study evaluated the effectiveness and safety of tofacitinib in Indian AxSpA patients in a real-world setting.
Methods
This single-centre, retrospective study at the Indian Spinal Injuries Centre (Delhi) reviewed records of 100 active AxSpA patients treated with generic tofacitinib 5 mg twice daily (BID) for 24 weeks. AxSpA was classified according to the Assessment of Spondyloarthritis International Society classification criteria. Efficacy was evaluated based on change in Ankylosing Spondylitis Disease Activity Score C-Reactive Protein (ASDAS-CRP) at 24 weeks. Safety was evaluated based on reported adverse events (AEs).
Results
A total of 100 patients with active AxSpA were treated with tofacitinib 5 mg BID for 24 weeks (23 received tofacitinib monotherapy and 77 received tofacitinib plus on-demand nonsteroidal anti-inflammatory drugs [NSAIDs]). 88 were biologic-naïve, and 12 patients had previously received biologic therapy. At week 24, ASDAS-CRP significantly decreased from 2.94 ± 0.8 to 1.18 ± 0.58 (mean difference 1.76; 95% CI: 1.56-1.96; P < .001). CRP levels declined from 13.85 ± 9.6 to 4.69 ± 3.2 (mean difference 9.16; 95% CI: 7.23-11.09; P < .001). Inactive disease (ASDAS-CRP < 1.3) was achieved in 71% of patients. Tofacitinib was well tolerated with a low incidence of AEs.
Conclusion
This retrospective real-world study supports the efficacy and safety of generic tofacitinib and its role as an NSAID-sparing agent in Indian patients with active AxSpA.
Zitieren
APA
Kapoor, S., Bondge, B., A., V., & P., S. (2026). Real-world Experience With Generic Tofacitinib in Axial Spondyloarthritis From North India. Indian Journal of Rheumatology. https://doi.org/10.1177/09733698261488955
Vancouver
Kapoor S, Bondge B, A. V, P. S. Real-world Experience With Generic Tofacitinib in Axial Spondyloarthritis From North India. Indian Journal of Rheumatology. 2026. doi:10.1177/09733698261488955
BibTeX
@article{Kapoor2026,
author = {Kapoor, Sanjiv and Bondge, Babita and A., Vivekanand and P., Shiv},
title = {Real-world Experience With Generic Tofacitinib in Axial Spondyloarthritis From North India},
journal = {Indian Journal of Rheumatology},
year = {2026},
doi = {10.1177/09733698261488955}
}
EUVIMED